Cemiplimab shows promising early outcomes for advanced cutaneous squamous-cell carcinoma

This open-label multicenter study evaluated the human monoclonal antibody, cemiplimab, for treatment of advanced cutaneous squamous-cell carcinoma. Cemiplimab is a high-affinity monoclonal antibody directed against programmed death 1 (PD-1).
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553